FDA Hits Guardian Drug for Lack of Quality Controls, Secure Data Post author:Sam Post published:April 11, 2017 Post category:Drug Industry Daily The FDA cited Guardian Drug Company over quality and data storage issues. Source: Drug Industry Daily You Might Also Like Five Deaths Draw Partial Clinical Hold for Ovarian Cancer Trials June 16, 2023 AstraZeneca’s Checkpoint Inhibitor Imfinzi Flops in Cervical Cancer Trial March 24, 2022 FDA Guidances Focus on Trials of Crohn’s Disease, Ulcerative Colitis Drugs April 28, 2022
